patent.fyi
Applications  /  US 2026/0356814
United States Patent Application Publication

US 2026/0356814 A1

Published
Nov 12, 2026
Filed
Aug 29, 2023
Earliest date on the face
Aug 29, 2022
Classification
C07D 401/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Nitrile at the R1 position

What ifWhat if R1 were a nitrile directly attached through its carbon atom?
Claim language“H, halo, OH, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl), and N(C1-6alkyl)2”

The linear C≡N group places a dipole along the attachment axis. Its terminal nitrogen provides a hydrogen-bond acceptor and remains uncharged near neutral pH.

1.2Methylsulfonyl at the R2 position

What ifWhat if R2 were a methylsulfonyl group attached through sulfur?
Claim language“H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl), and N(C1-6alkyl)2”

The –S(=O)₂CH₃ group presents two hydrogen-bond acceptor oxygens from a tetrahedral sulfur center. The methyl group occupies the remaining position on sulfur and provides a small nonpolar surface.

1.4Carbocyclic bridge across R4 and R5

What ifWhat if a three-methylene bridge joined the R4 and R5 attachment sites?
Claim language“linked together to form O—(CH2)1-2O”

A –CH₂–CH₂–CH₂– tether closes a five-membered carbocycle with the two adjacent scaffold atoms. Ring closure constrains the geometry at both sites and presents a nonpolar surface.

1.5Ethynylene linker between terminal groups

What ifWhat if L were a two-carbon ethynylene linker between X and A?
Claim language“C1-6alkylene, C2-6alkenylene”

A –C≡C– unit connects X and A through two sp-hybridized carbons. The triple bond places the two attachment vectors on a common axis and fixes their separation.

1.6Cyclopropyl on the ra nitrogen

What ifWhat if Ra were a cyclopropyl group bonded directly to nitrogen through a ring carbon?
Claim language“H and C1-6alkyl”

The three-membered carbon ring occupies a compact volume next to nitrogen. Its two remaining carbons have a fixed relationship to the attachment carbon because they form part of the same ring.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Sulfonamide linkage for the pendant group

An aryl sulfonamide replaces the aryl carboxamide at R4, and R5 is hydrogen. The pendant group attaches through the sequence aryl–SO₂–NH–CH₂–cyclopropyl, with the aryl carbon bonded directly to sulfur. Coupling the corresponding R4 arylsulfonyl chloride with cyclopropylmethylamine forms the sulfonamide.

Parameter or scale variation

Miniaturized indoline concentration response assay

A 384-well plate holds 8,000 receptor-expressing cells per well in a final assay volume of 40 microliters. An eight-point, threefold dilution series starts at 10 micromolar, with three wells per concentration and a matched vehicle concentration throughout. A fluorescence reader records 10 seconds of baseline and 90 seconds after addition, and the peak baseline-corrected signal enters a four-parameter concentration response fit.

Timed pulses for receptor response recovery

Three parallel perfusion chambers contain the same serotonin receptor-expressing cell line and receive a 30-second pulse of one indoline derivative at its measured half-maximal concentration. The chambers receive fresh buffer for 2, 5, or 15 minutes before a second 30-second pulse at the same concentration. The ratio of the second peak calcium signal to the first gives the response recovery at each wash interval.

Combination with existing systems

Perfused receptor assay with downstream sampling

A microfluidic perfusion cartridge contains parallel chambers for a serotonin receptor-expressing cell line and its parental line. A switching valve delivers assay buffer, indoline solution, and wash buffer to both chambers while a fluorescence microscope records intracellular calcium. A fraction collector captures the outlet stream from each chamber separately for liquid chromatography and mass spectrometry, which measures indoline recovery during each pulse and wash.

Automated or data-driven variant

Automated retesting of fitted response curves

A liquid handler prepares dilution series from an indoline stock plate and dispenses them into assay plates with vehicle and serotonin controls. Software imports the plate map and fluorescence traces, subtracts each well's baseline, and fits peak responses to a four-parameter logistic model. When the fitted midpoint falls between tested concentrations and its 95 percent confidence interval spans more than tenfold, the software schedules a repeat with closer concentration spacing around the midpoint.

Specific version of a part

Ethyl on the rb nitrogen

Rb is an ethyl group bonded to nitrogen through its methylene carbon. The terminal methyl group extends one carbon beyond that attachment point.

Cyclobutyl terminal group

A is a cyclobutyl group joined to L through one ring carbon. The four saturated carbons form a puckered ring that provides a compact nonpolar terminal group.

Fluoro and methoxy on phenyl

A is a phenyl group with fluorine at position 3 and methoxy at position 4, counted from its attachment to L. The methoxy oxygen provides a hydrogen-bond acceptor, and the fluorine occupies the adjacent ring position.

Morpholine ring at the nitrogen

R60 and R61 form a –CH₂–CH₂–O–CH₂–CH₂– bridge whose two ends bond to the same nitrogen. The resulting six-membered ring places the ether oxygen opposite the nitrogen.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0336224 A1
Published
Nov 13, 2014
Filed
Oct 18, 2012
Class
C07D 413/06
Document BUS 2016/0067245 A1
Published
Mar 10, 2016
Filed
Nov 19, 2015
Class
A61K 31/496
Claim 1
Document A
Document B
1.1R1 and R1′ are independently selected from H, halo, OH, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl), and N(C1-6alkyl)2
or a pharmaceutically acceptable salt thereof, wherein Each Rx is independently H, halo, OR, C1-C6 alkyl, (CR2)0-1CN, OR, C(O)OR10, C3-C10 cycloalkyl, NR6C(O)R10, NR6SO2R8, or NH2, said alkyl and cycloalkyl are optionally substituted with 1 to 3 substituents selected from halo, OR and C1-C6 alkyl; Each R is independently H, C1-C6 alkyl or C3-C10 cycloalkyl, said alkyl and cycloalkyl are optionally substituted with 1 to 4 halo substituents;
A · US 2014/0336224 A1 · ¶
1.2R2 and R2′ are independently selected from H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl), and N(C1-6alkyl)2
R2 is selected from the group consisting of cyano; halo;
B · US 2016/0067245 A1 · ¶
1.3Q is selected from Q1, Q2, Q3, Q4, Q5, and Q6: is a single bond or a double bond provided that when in Q1 is a double bond then R9 and R15 are not present, when in Q2 is a double bond then R17 and R25 are not present, and when in Q5 is a double bond then R48 and R57 are not present
1.4one or both of R4 and R5 is independently selected from H, halo, C1-6alkyl, and C1-6alkoxy, or R4 and R5 are linked together to form O—(CH2)1-2O, or one of R4 and R5 is selected from X-L-A and the other of R4 and R5 is selected from H, halo, C1-6alkyl, and C1-6alkoxy, X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa, and NRbC(O)NRa
R4 is 1) H, 2) —NR6S(O)2R8, 3) (CR2)v—S(O)pR8, 4) C1-C6 alkyl, 5) C3-C6 cycloalkyl, 6) —(CH2)0-1-CN, 7) halo, 8) —C(O)OR8, 9) —NH2, 10) —NO2, 11) —OR, 12) —(CRa2)t-S(O)2R8, 13) —NR6C(O)R10, 14) —NR6C(O)OR10, 15) aryl, 16) heterocyclyl, or 17) heteroaryl; where said alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl are optionally substituted with one to three OR, C1-C6 alkyl or halo substituents;
A · US 2014/0336224 A1 · claim 1
1.5L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2-6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2-6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2-6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2-6alkenyleneOC(O)NRb, C1-6alkyleneNRbc(O)O, C2-6alkenyleneNRbc(O)O, C1-6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb, and C2-6alkenyleneNRbc (O) NRb
1.6Ra is selected from H and C1-6alkyl
C1-3alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C1-3alkyl, C1-3alkyloxy, C1-3alkyloxyC1-3alkyl, hydroxyC1-3alkyl, cyano, hydroxyl, amino, C(═O)R′, C(═O)OR′, C(═O)NR′R″, mono- or di(C1-3alkyl)amino, morpholinyl, (C3-7cycloalkyl)C1-3alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R′ and R″ a
B · US 2016/0067245 A1 · ¶
1.7Rb is selected from H, C1-6alkyl, and A
1.8A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoieties independently selected from O, S, S(O), SO2, N and NR64 and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoieties_independently selected from O, S, S(O), SO2, N and NR64
R1 is 1) H, 2) CN, 3) OR, 4) C1-C6 alkyl, 5) C3-C6 cycloalkyl 6) aryl, 7) heteroaryl, 8) heterocyclyl, 9) C(O)R10, 10) C(O)NRR6, or 11)C(O)OR10; wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one to three CF3, OR, CN, C1-C6 alkyl, or halo substituents;
A · US 2014/0336224 A1 · claim 1
C1-3alkyl substituted with one or more independently selected halo substituents; unsubstituted C3-7cycloalkyl;
B · US 2016/0067245 A1 · ¶
1.9wherein the phenyl, EC3-6cycloalkyl, 3- to 6-membered heterocycloalkyl, and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, and OC1-4alkyl
C3-7cycloalkyl substituted with 1 or 2 substituents independently selected from C1-3alkyl, C1-3alkyl substituted with one or more independently selected halo substituents or hydroxyl; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C1-3alkyl, hydroxyC1-3alkyl, C1-3alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, C1-3alkyloxy-C1-3alkyl, C1-3alkyloxy, and
B · US 2016/0067245 A1 · ¶
1.10R3 and R6 are independently selected from H, halo, OH, C1-6alkyl, and C1-6alkoxy
1.11R8, R9, R10, R11, R13, R14, R15, R16, R17, R18, R19, R21, R22, R23, R24, R25, R26, R27, R28, R30, R31, R32, R33, R34, R35, R36, R37, R38, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R52, R53, R54, R55, R56, R57, R58, R59, R62, and R63 are independently selected from H, halo, and C1-6alkyl
Each R9 is independently halo, CN, OCF3, C1-C6 alkyl, OR, NH2, aryl or heteroaryl, where said alkyl, aryl or heteoraryl may be optionally substituted with one to three CN, OCF3, OR, C1-C6 alkyl, NH2 or halo substituents;
A · US 2014/0336224 A1 · claim 1
wherein each W1d, W1e, W2e and W1f is independently selected from CH and N; each R7d, R7e, R7f, R7g, R8d, R8e, R8f, R8g is independently selected from hydrogen, methyl and fluoro; or each CR7dR8d, CR7eR8e, CR7fR8f, CR7gR8g form a carbonyl group; each R9d, R9e, R9f, and R9g is fluoro; each q1, q2, q3 or q4 is independently selected from 0, 1 and 2; r is 0 or 1; s is 0 or 1; each R3b and R3c is selected from the group consisting of C1-3alkyl;
B · US 2016/0067245 A1 · ¶
1.12R12, R20, R29, R39, and R51 are independently selected from H, C1-6alkyl, C(O)C1-6alkyl, and C(O)-A′ R60 and R61 are independently selected from H and C1-6alkyl or one of R60 and R61 is C(O)-A′ and the other is selected from H and C1-6alkyl wherein A′ is selected from Y, O—Y, and O—C1-4alkylene-O—C(O)—Y Y is selected from C7-30alkyl and C7-30alkenyl or R60 and R61, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR65 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl, and OC1-4alkyl R64 and R65 are independently selected from H and C1-6alkyl all available hydrogen atoms are optionally and independently replaced with a fluorine atom or a chlorine atom and all available atoms are optionally replaced with alternate isotope thereof, provided when Q is Q6, then the compound of Formula I-A comprises D, when Q is Q3 or Q4, then R1, R1′, R2, R2′, R3, R4, R6, R26, R27, R28, R30 to R35, R36, R37, R38, and R40 to R47 are not all H, when R5 is H or OCH3, and R29 or R39 is CH3 when Q is Q4 and R1, R1′, R2, R2′, R3, R4, R6, R38, and R40 to R47 are all H, then R36 and R37 are not both D, when R39 is CD3.
The notation “C1-3alkyl substituted with one or more independently selected halo substituents” as used herein alone or as part of another group, defines an alkyl group as defined above, substituted with 1, 2, 3 or more halogen atoms, such as fluoromethyl; difluoromethyl; trifluoromethyl; 2,2,2-trifluoroethyl; 1,1-difluoroethyl; 3,3,3-trifluoropropyl.
B · US 2016/0067245 A1 · ¶ 48

An empty cell means only that no passage was reproduced there.

Statements in these documents
Despite significant therapeutic advances in the treatment of hypertension and heart failure, the current standard of care is suboptimal and there is a clear unmet medical need for additional therapeutic/pharmacological interventions.
A · US 2014/0336224 A1 · ¶ 7
This invention addresses those needs by providing compounds and compositions which may be useful for the treatment or prevention of hypertension, heart failure, other cardiovascular disorders and other aldosterone disorders.
A · US 2014/0336224 A1 · ¶ 7
The present invention relates to novel triazolo[4,3-a]pyridine derivatives which are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved.
B · US 2016/0067245 A1 · ¶ 2
Furthermore, glutamate is at the centre of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission.
B · US 2016/0067245 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0356814 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356814/, SHA-256 395af1b98f5345854a7caed092b3f09025cf6738a566473ac1dc3337d429f13c
First published
Permanent addresshttps://patent.fyi/US20260356814/
Content fingerprint (SHA-256)395af1b98f5345854a7caed092b3f09025cf6738a566473ac1dc3337d429f13c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi